Home · Safety · FDA Alerts on GLP-1 Drugs in 2026

FDA Alerts on GLP-1 Drugs in 2026

Dated FDA and federal actions, and what each means for you.

Released: Last reviewed:

Short answer · November 8, 2026

What has FDA done about compounded GLP-1s in 2026? In 2026 FDA proposed on April 30 to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list (91 FR 23431; comments closed July 30, with no final decision found as of October 15), and on September 18 it sent warning letter 738238 to Empower Pharmacy. That letter says certain compounded tirzepatide and semaglutide products appear to be essentially copies of approved drugs. FDA's GLP-1 page, current as of October 1, 2026, tells patients to discard a multi-dose vial within 28 days after first use and not to use injectable GLP-1s that arrive warm.

FDA and federal actions on GLP-1s in 2026 that matter to cash-pay patients
DateActionWhat it meansSource · read
April 30, 2026FDA proposes not to put tirzepatide, semaglutide or liraglutide on the 503B bulks list (91 FR 23431)Outsourcing facilities could not compound them from bulk drug substance if finalized; comments closed July 30 (91 FR 38719); no final decision found as of October 15federalregister.gov · October 15, 2026
September 18, 2026Warning letter 738238 to Empower Pharmacy (posted September 22)FDA says some compounded tirzepatide and semaglutide products with additives "appear to be essentially copies" of approved drugs; cites insanitary conditionsfda.gov · October 15, 2026
September 23–24, 2026Warning letters 737806 and 737810 to two websites selling unapproved "generic" semaglutide (posted October 6)Online "generic semaglutide" is unapproved and misbrandedfda.gov · October 15, 2026
September 29, 2026Charges announced in a counterfeit Ozempic distribution caseBuy brand GLP-1s only from licensed pharmacies; an indictment is an allegationfda.gov · October 15, 2026
October 1, 2026FDA updates its page on unapproved GLP-1 drugsDiscard multi-dose vials within 28 days of first use; do not use injectable GLP-1s that arrive warm; 990 / 730+ adverse-event reports for compounded semaglutide / tirzepatide through May 31fda.gov · November 8, 2026

What to do with this

  • Ask your program which pharmacy fills your prescription and whether it is a 503A pharmacy or a 503B outsourcing facility; check it on our pharmacy verification page.
  • If your vial is a multi-dose vial, write the first-use date on it and discard it after 28 days, even if the pharmacy label says longer.
  • Do not inject medication that arrived warm; read GLP-1 arrived warm? FDA’s cold-chain warning.
  • Report problems to FDA’s MedWatch program.

Background on what compounding is and is not: compounding risks and our 503A vs 503B explainer. All developments: GLP-1 news.

FAQ

What has FDA done about compounded GLP-1s in 2026?

In 2026 FDA proposed on April 30 to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list (91 FR 23431; comments closed July 30, with no final decision found as of October 15), and on September 18 it sent warning letter 738238 to Empower Pharmacy. That letter says certain compounded tirzepatide and semaglutide products appear to be essentially copies of approved drugs. FDA's GLP-1 page, current as of October 1, 2026, tells patients to discard a multi-dose vial within 28 days after first use and not to use injectable GLP-1s that arrive warm.

Is compounded semaglutide now illegal?

No. State-licensed 503A pharmacies can still compound for individual prescriptions under federal conditions. FDA’s 503B proposal would affect outsourcing facilities if finalized, and its warning letters target specific companies and products. Compounded versions remain unapproved.

What did the Empower warning letter say?

FDA’s September 18, 2026 letter says Empower’s compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin appear to be essentially copies of FDA-approved products and that differences appeared pretextual, and it cites insanitary conditions for sterile products.

How many adverse events has FDA logged for compounded GLP-1s?

FDA’s page, current as of October 1, 2026, counts 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide through May 31, 2026. FDA says these are likely underreported and do not by themselves prove the drug caused the event.

Has FDA finalized the 503B exclusion?

Not as of our October 15, 2026 check of the Federal Register. The proposal (91 FR 23431) was announced April 30, 2026 and the comment period closed July 30, 2026 (91 FR 38719).

Sources

  1. Federal Register — 91 FR 23431, proposed 503B bulks-list decision (May 1, 2026) (read October 15, 2026)
  2. Federal Register — 91 FR 38719, comment period extended to July 30, 2026 (read October 15, 2026)
  3. U.S. FDA — Warning letter 738238, Empower Pharmacy (dated September 18, 2026) (read October 15, 2026)
  4. U.S. FDA — Warning letter 737806, onlinegenericmedicine.com (read October 15, 2026)
  5. U.S. FDA — Warning letter 737810, cheapmedicineshop.com (read October 15, 2026)
  6. U.S. FDA — Charges in counterfeit Ozempic investigation (September 29, 2026) (read October 15, 2026)
  7. U.S. FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026) (read November 8, 2026)
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.